Baxdrostat
CinCor Pharma
[]
cincor pharma announces late-breaking presentation of phase 2 brightn data on baxdrostat in treatment-resistant hypertension at the 2022 american heart association scientific sessions 
We provide a balanced view on small cap biotech equities.